证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司 投资者关系活动记录表 编号：2022-009 | --- | --- | --- | --- | |-------------------------|-----------------------------------------|----------------------------|--------------------------------------------------------------------------------------------------------------------| | | | | | | | □特定对象调研 □媒体采访 | □分析师会议 ■业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | 通过"路演中"网络平台参与公司 会的投资者 | 2022 | 年半年度网上业绩说明 | | 时间 | 2022 年 9 月 1 日 | | | ...

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-010 | --- | --- | --- | |-------------------------|-------------------------------|----------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | 媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | | | | 信达证券 | 张弛、王明路；前海人寿 黄皓；浙商证券 金豪； | | | 平安基金 | 江正青；中金资管 莫华寅、樊荣；建信基金 李峰； | | 参与单位名称及 人员姓名 | 国联证券 | 高远，安柯，黄荣达，赵润笛；信达澳亚 王宇豪； | | | 英大资产 | 刘青青；天弘基金 刘佳欣； 通过"路演中"平台参加调研活动的若干投资者 | | | 2022 年 10 月 28 日 | 1 ...

Financial Performance - The company's revenue for Q3 2022 was ¥194,061,643.88, a decrease of 7.42% compared to the same period last year, and a year-to-date revenue of ¥561,689,616.37, down 12.96% year-on-year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥20,873,546.27, a decline of 37.07% year-on-year, with a year-to-date net profit of ¥72,847,006.41, down 18.55%[8]. - The company's basic earnings per share for Q3 2022 was ¥0.0520, down 37.12% year-on-year, with diluted earnings per share also at ¥0.0520[7]. - Total operating revenue for the third quarter was ¥561,689,616.37, a decrease of 12.94% compared to ¥645,340,755.20 in the previous year[35]. - The net profit for the period was 9,136,788.75, a decrease of 41.1% compared to 15,547,817.36 in the previous period[38]. - The total comprehensive income attributable to the parent company's owners was 73,279,409.35, down from 89,412,584.34 in the previous period[42]. - The total operating profit was 82,354,030.96, a decrease of 21.5% from 104,903,485.57 in the previous period[38]. Cash Flow and Liquidity - The company's cash flow from operating activities for the year-to-date period was ¥77,571,456.00, an increase of 28.93% year-on-year[7]. - The net cash received from operating activities increased by 40.23% to ¥21,975,422.91, primarily due to higher government subsidies received[19]. - The total cash inflow from operating activities was 513,646,935.93, compared to 537,271,102.83 in the previous period[45]. - The cash outflow for purchasing goods and services was 114,008,774.73, down from 159,198,374.92 in the previous period[45]. - The cash flow from investment activities was -55,641,234.56, slightly worse than -50,761,485.99 in the previous period[45]. - The cash and cash equivalents at the end of the period were 422,039,676.26, down from 465,232,335.71 at the end of the previous period[45]. - The net increase in cash and cash equivalents improved by 50.98% to -¥7,928,170.15, influenced by increased government subsidies and reduced tax payments[22]. Research and Development - The company increased its R&D investment by 32.76% year-on-year, with R&D expenses rising by 53.39% compared to the same period last year[8]. - R&D expenses increased by 53.39% to ¥38,905,107.64 compared to ¥25,363,574.05 in the same period last year, primarily due to increased investment in R&D[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,814,894,636.19, reflecting a 2.45% increase from the end of the previous year[7]. - The company's total liabilities decreased to ¥496,022,630.08 from ¥505,563,562.44, indicating improved financial health[34]. - Non-current assets increased to ¥894,207,851.78 from ¥877,385,749.10, reflecting ongoing investments in long-term resources[32]. - Accounts receivable increased by 32.12% to ¥216,126,422.05 compared to the end of the previous year, primarily due to an increase in customer receivables[17]. - Inventory levels were reported at ¥122,559,224.60, slightly down from ¥127,437,191.78, suggesting effective inventory management[32]. Other Financial Metrics - The company's gross profit margin decreased due to a 22.69% decline in production volume, leading to increased unit production costs[8]. - Financial expenses surged by 354.21% to ¥6,663,004.62, attributed to decreased interest income from bank deposits and increased interest expenses from convertible bonds[18]. - Other income rose by 175.77% to ¥12,936,740.52, mainly due to increased government subsidies received during the period[18]. - The fair value change income increased by 183.23% to ¥1,518,648.22, mainly due to the increase in financial products[18]. - The company experienced a 94.33% increase in credit impairment losses to -¥3,141,569.14, primarily due to an increase in accounts receivable[18]. - The tax expense decreased by 41.23% to ¥9,136,788.75, mainly due to a reduction in total profit and increased R&D expense deductions[18]. Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[35]. - The company plans to independently operate the "Quchang" brand of orlistat capsules, which is currently in the market introduction phase[7]. Reporting Information - The third quarter report of Chongqing Huasen Pharmaceutical Co., Ltd. is unaudited[49]. - The report was released on October 26, 2022[49].

Financial Performance - The company reported a total revenue of CNY 500 million for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was CNY 80 million, up 20% compared to the same period last year[21]. - The company's operating revenue for the reporting period was ¥367,627,972.49, a decrease of 15.63% compared to the same period last year[28]. - Net profit attributable to shareholders was ¥51,973,460.14, down 7.63% year-on-year[28]. - The net profit after deducting non-recurring gains and losses was ¥41,768,313.25, reflecting a decline of 21.26% compared to the previous year[28]. - The company achieved operating revenue of 368 million yuan, a decrease of 15.63% compared to the same period last year[44]. - The company reported a net increase in cash and cash equivalents of ¥3,575,814.82, a decline of 91.40% compared to ¥41,590,148.79 in the previous period, mainly due to increased investments in financial products and R&D-related long-term assets[61]. - The pharmaceutical industry segment accounted for 81.99% of total revenue, with a year-on-year decline of 18.45%[63]. - The revenue from hormone and endocrine function drugs plummeted by 78.15%, attributed to a significant drop in sales of low-margin cooperative products[68]. Research and Development - The company plans to invest CNY 200 million in R&D for new drug development in the next fiscal year[21]. - R&D investment increased by 62.93% compared to the previous year, with R&D expenses rising by 24.12%[46]. - The company has four independently developed Class 1 innovative drugs for oncology in the pipeline, targeting various solid tumors including lung cancer, breast cancer, colorectal cancer, and pancreatic cancer[41]. - The company emphasizes research and development innovation, continuously increasing R&D investment to support the development of First-In-Class and Best-In-Class drugs[41]. - The company has established platforms for functional genomics screening, small molecule drug design, and pharmacokinetic testing to enhance drug development capabilities[41]. - The company is focused on differentiated R&D pipelines to create an internationally competitive innovative drug development team[41]. - The company has 23 projects in the pipeline for generic drugs and raw materials, 1 for improved innovation, 2 for traditional Chinese medicine, and 4 for special medical foods[48]. - The company expects to obtain 1-2 clinical approval documents for innovative drugs between 2023 and 2024[48]. Market Expansion - User data indicates a 25% increase in the number of active customers, reaching 1 million by the end of June 2022[21]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 30%[21]. - Future guidance estimates a revenue growth of 20% for the second half of 2022, driven by new product launches and market expansion efforts[21]. - The company is actively expanding its market presence in various provinces, including Chongqing, Jilin, and Guangdong[41]. - The company aims to create a billion-level product group centered around five key products while expanding its market presence in both public and private healthcare sectors[52]. Product Development - A new product line of five proprietary traditional Chinese medicines was launched, contributing to 10% of total sales in the first half of 2022[21]. - The company is developing four special medical food projects, with products already marketed as special dietary foods prior to obtaining production permits[37]. - The company has completed the construction of the special medical food production line and is currently advancing the quality system certification for this production line[56]. - The company launched new products including Cang'erzi capsules and continues to expand its product range, which may support future revenue growth[44]. - Core products such as the exclusive traditional Chinese medicine Gan Zhi Bing Mei Pian, Liu Wei An Shen Jiao Nang, and the emergency medication injection of Gabapentin achieved growth rates of 4.98%, 16.46%, and 20.29% respectively compared to the previous year[52]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[6]. - The company’s financial expenses increased by 35.87% to ¥4,333,868.76, mainly due to reduced interest income from bank deposits and increased amortization of convertible bonds[58]. - The company has no significant asset impairment risks associated with its overseas assets, which total ¥4,014,723.71, representing 0.31% of net assets[76]. - The company has no significant guarantees or leasing situations reported[163]. - The company has no major contracts or performance issues reported during the period[166]. Environmental and Social Responsibility - The company reported a total wastewater discharge of 293.138 tons per year for COD, meeting the regulatory standards with no exceedances[117]. - The company also reported a total wastewater discharge of 21.375 tons per year for NH3-N, complying with the established limits[117]. - The company has maintained a 100% pass rate in product quality inspections across various regulatory checks, with no quality incidents reported[121]. - The company has been recognized as a "National Worker Pioneer" for its workshop, maintaining a record of 100% quality compliance and zero accidents over 22 years[121]. - The company donated 300,000 yuan to local health centers for COVID-19 response efforts during the reporting period[122]. - The company has installed a 24-hour online monitoring system for wastewater discharge, receiving recognition from the local government for its environmental efforts[122]. - The company has established a comprehensive environmental management system, ensuring compliance with national and local regulations[117]. - The company has been awarded the title of "Advanced Private Enterprise in Poverty Alleviation" for its contributions to local communities[122]. Corporate Governance - The company plans to enhance its talent management and performance evaluation systems to foster development vitality and establish a competitive workforce[129]. - The company has committed to a long-term strategy for sustainable development, enhancing its capital strength and risk resistance capabilities[126]. - The company has ensured that all commitments made by major shareholders and executives regarding shareholding are fulfilled[138]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[149]. - There were no significant lawsuits or arbitration matters reported during the period[150]. - The company did not engage in any major related party transactions during the reporting period[151].

重庆华森制药股份有限公司 2022 年第一季度报告全文 证券代码：002907 证券简称：华森制药 公告编号：2022-032 重庆华森制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------------------------|-------------------------------|-------------------------------|- ...

重庆华森制药股份有限公司 2021 年年度报告全文 重庆华森制药股份有限公司 2021 年年度报告 2022-017 2022 年 04 月 1 重庆华森制药股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人游洪涛、主管会计工作负责人刘小英及会计机构负责人(会计主 管人员)彭晓燕声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司 2021 年度报告涉及的未来计划等前瞻性陈述，不构成公司对投资者的 实质承诺，请投资者注意投资风险。风险因素详见本报告第三节"管理层讨论 与分析"中"十一、公司未来发展的展望（三）经营可能面对的风险"相关内 容。 公司经本次董事会审议通过的利润分配预案为：以未来实施分配方案时股 权登记日的总股本为基数，向全体股东每 10 股派发现金红利 0.50 元（含税）， 送红股 0 股（含税），不以公积金转增股本。 2 重庆华森制药股份有限公司 2021 年年度报告 ...

证券代码：002907 证券简称：华森制药 公告编号：2021-079 债券代码：128069 债券简称：华森转债 重庆华森制药股份有限公司 关于参加"重庆辖区上市公司 2021 年投资者 网上集体接待日活动"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为提高公司规范运作水平，进一步做好投资者关系管理工作，重庆华森制药股 份有限公司（以下简称"公司"）将参加由重庆上市公司协会联合上证所信息网络 有限公司、深圳市全景网络有限公司举办的"重庆辖区上市公司 2021 年投资者网 上集体接待日活动"。本次活动将于 2021 年 11 月 25 日（星期四）15:00～17:00 举 行，投资者可以登陆全景·路演天下（http://rs.p5w.net）进入本公司互动平台参与 交流。 届时，公司有关高级管理人员将参与本次活动，并通过网络在线交流形式，就 投资者所关心的问题，与投资者进行"一对多"形式的在线沟通。欢迎广大投资者 踊跃参与。 特此公告 重庆华森制药股份有限公司 董事会 2021 年 11 月 19 日 ...

重庆华森制药股份有限公司 2021 年第三季度报告 □ 是 √ 否 1 证券代码：002907 证券简称：华森制药 公告编号：2021-072 重庆华森制药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------------------------ ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[16]. - The net profit attributable to shareholders was 80 million CNY, which is a 20% increase from the previous year[16]. - Future guidance estimates a revenue growth of 12% for the second half of 2021, projecting total revenue to reach approximately 560 million CNY[16]. - The company's operating revenue for the first half of 2021 was ¥435,735,817.85, representing a year-on-year increase of 14.82% compared to ¥379,486,321.32 in the same period last year[21]. - The net profit attributable to shareholders decreased by 10.45% to ¥56,268,345.12 from ¥62,831,457.81 in the previous year[21]. - The company achieved a revenue of 436 million yuan in the reporting period, representing a year-on-year growth of 14.82%[35]. - The company reported a revenue of 370 million yuan for the pharmaceutical industry, representing a year-on-year growth of 16.33%[44]. - The company reported a total revenue of approximately 401.7 million yuan for the first half of 2021, which shows a decrease compared to the previous year's figures[188]. Research and Development - The company plans to invest 200 million CNY in R&D for new products and technologies in the upcoming year[16]. - R&D investment increased by 33.39% compared to the previous year, focusing on innovative drugs and high-end formulations[37]. - The company has four self-developed innovative oncology drugs in the pipeline, targeting various solid tumors[35]. - The company aims to obtain its first clinical approval for an innovative drug by 2022 or 2023[35]. - The company is actively engaged in new drug research and development, focusing on innovative pharmaceutical solutions to enhance market competitiveness[122]. - The company has allocated approximately 3.08 million yuan for research and development of new technologies[188]. Market Expansion - The company is focusing on market expansion in Southeast Asia, targeting a 25% increase in market share by the end of 2022[16]. - The company is expanding into the special medical food sector, aiming to establish the first production base for special medical food in the Sichuan-Chongqing region[29]. - The company is actively pursuing compliance with international regulatory standards to facilitate entry into the European market by 2023[16]. - The company is actively pursuing market expansion strategies, including the development of new sales channels and partnerships[72]. - The company plans to continue its focus on research and development of new pharmaceutical products and technologies, aiming to enhance its market position[72]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[121]. User Engagement - User data indicates that the company has expanded its customer base by 10% in the first half of 2021, reaching a total of 1.2 million active users[16]. - There was a notable increase in user data, with a reported increase in customer engagement and sales channels[72]. - User data shows an increase in customer engagement, with a 20% rise in active users compared to the previous reporting period[121]. - The company reported a significant increase in user data engagement, with a focus on improving customer satisfaction and retention[188]. Financial Health - The net cash flow from operating activities decreased by 40.09% to ¥41,362,886.21 from ¥69,038,463.50[21]. - Total assets increased by 5.33% to ¥1,813,211,798.64 from ¥1,721,413,431.40 at the end of the previous year[21]. - The company’s total assets at the end of the reporting period are 1,119,200,000 CNY, showing a stable asset base[192]. - The company reported a cash and cash equivalents balance of CNY 522.99 million at the end of the first half of 2021, an increase from CNY 395.17 million at the end of the first half of 2020[181]. - The company maintained a credit rating of AA- with a stable outlook from China Chengxin International Credit Rating Co., Ltd.[154]. - The company reported a net profit distribution to shareholders of -11,247,270 CNY, indicating a loss in profit allocation compared to the previous period[191]. Strategic Initiatives - The company has initiated a new digital marketing strategy aimed at increasing online sales by 30% over the next six months[16]. - The company is enhancing its sales team's academic promotion capabilities through training programs and initiatives to improve market competitiveness[44]. - The company is focusing on expanding its CMO business to improve capacity utilization and reduce production costs[45]. - The company is advancing its cGMP certification process, which is crucial for internationalizing its drug quality standards and expanding into high-end formulation projects in Europe and the U.S.[45]. - The company aims to improve operational efficiency, targeting a reduction in production costs by 10% through process optimization[121]. Compliance and Governance - The company is committed to maintaining compliance with regulatory requirements and ensuring the accuracy of financial disclosures[126]. - The company has achieved compliance with environmental discharge standards for wastewater, waste gas, noise, and solid waste, with no pollution incidents or penalties reported[92]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[98]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[103]. Shareholder Information - The company approved the repurchase and cancellation of 14,500 restricted stocks at a price of 10.18 CNY per share due to two employees losing their eligibility for the incentive plan[82]. - The largest shareholder, Chengdu Local Construction Mechanization Engineering Co., Ltd., holds 46.83% of the total shares, amounting to 188,100,000 shares[135]. - The company has implemented a stock lock-up policy for executives, with 25% of their shares being released annually[132]. - The conversion of "Huason Convertible Bonds" resulted in a total of 12,550 shares converted as of June 30, 2021[130].

Financial Performance - The company's operating revenue for Q1 2021 was ¥230,001,139.60, representing a 34.88% increase compared to ¥170,526,616.65 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2021 was ¥36,473,743.54, up 30.98% from ¥27,846,825.73 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥35,346,886.09, reflecting a 38.59% increase from ¥25,504,415.52 year-on-year[9]. - Basic earnings per share for Q1 2021 were ¥0.0911, which is a 30.89% increase from ¥0.0696 in the previous year[9]. - The company reported a net profit margin improvement, with net profit for the quarter showing a significant increase compared to the previous year[67]. - The total profit for the current period was ¥42,655,085.41, up from ¥32,750,236.58 in the previous period, indicating strong overall performance[74]. Cash Flow - The net cash flow from operating activities reached ¥17,248,596.47, a significant increase of 90.05% compared to ¥9,075,927.29 in the same period last year[9]. - Cash flow from operating activities saw a significant increase of 90.05%, reaching CNY 17,248,596.47, attributed to higher sales collections and reduced sales expenses[32]. - The cash flow from operating activities was ¥151,995,434.30, compared to ¥145,064,102.39 in the previous period, showing a positive trend in cash generation[82]. - Operating cash inflow totaled ¥155,786,643.10, an increase from ¥150,568,616.49 in the previous period[86]. - Total cash inflow from operating activities was ¥141,066,440.95, slightly down from ¥147,541,652.54[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,753,552,889.22, marking a 1.87% increase from ¥1,721,413,431.40 at the end of the previous year[9]. - The total assets of the company reached approximately ¥1.75 billion, up from ¥1.72 billion, indicating a growth of around 1.9%[56]. - The company's total liabilities were approximately ¥534.24 million, a slight decrease from ¥539.59 million, indicating a reduction of about 1%[54]. - Total liabilities reached CNY 524,573,753.02, compared to CNY 516,590,007.72 in the previous period, indicating a slight increase of 1.9%[64]. - The company's equity attributable to shareholders reached approximately ¥1.22 billion, an increase from ¥1.18 billion, reflecting a growth of about 3.5%[56]. Research and Development - Research and development expenses increased by 35.83% to CNY 6,611,832.82, reflecting the company's commitment to enhancing R&D investments[29]. - Research and development expenses for the quarter were CNY 6,611,832.82, up from CNY 4,867,581.50, representing a growth of approximately 36%[67]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥1,382,781.42 during the reporting period[9]. - The company’s other income increased by 44.90% to CNY 1,588,496.07, mainly due to an increase in government subsidies[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,419[14]. - The company reported no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[43]. Investment and Financing Activities - The company reported a 91.66% decrease in short-term borrowings, down to CNY 1,000,901.39, due to the repayment of a substantial portion of bank loans[29]. - Cash inflow from financing activities was ¥6,000,000.00, while cash outflow totaled ¥11,151,435.84, leading to a net cash flow of -¥11,151,435.84[88]. Inventory and Receivables - The accounts receivable increased to approximately ¥202.74 million from ¥167.12 million, representing a significant rise of about 21.3%[48]. - Inventory levels increased to CNY 107,647,104.84 from CNY 105,927,369.21, indicating a slight rise of 1.1%[58]. Taxation - The company reported a tax expense of ¥6,181,341.87, which is higher than the previous period's ¥4,903,410.85, reflecting increased profitability[74]. - The company reported a 72.18% increase in taxes payable, amounting to CNY 14,135,020.06, primarily due to the accrual of income tax for the first quarter[29]. Other Information - The first quarter report for 2021 was not audited[107]. - The company has not engaged in any major contracts or significant external guarantees during the reporting period[43][54].